BOSTON, Jan 25 (Reuters) - Zafgen's stock tumbled as much as 11.5 percent on Monday after hedge fund Kerrisdale Capital said it has a short bet on the biopharmaceutical company's stock, arguing that U.S. regulators will not approve the sale of its obesity drug.
